Basic Stats
| LEI | 5493000MP9GU5S88NF42 |
| CIK | 1044378 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Biocept, Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| October 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2023 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2023 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 22, 2023 |
Biocept Reports Second Quarter 2023 Financial Results Exhibit 99.1 Biocept Reports Second Quarter 2023 Financial Results SAN DIEGO—(BUSINESS WIRE)-Aug. 14, 2023— Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June 30, 2023 and provides a business update. “Biocept’s primary focus is establishing our proprietary cerebrospinal fluid assa |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36284 Biocept, Inc. (Exact name |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 2, 2023 |
US09072V6002 / BIOCEPT INC / Lind Global Fund II LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Biocept, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 09072V600 (CUSIP Number) May 26, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| June 2, 2023 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.0001 per share, of Biocept, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G. June 2, 2023 LIND GLOBAL FUND II LP By: Lind Global Partners II LLC its Genera |
|
| May 25, 2023 |
424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-271355 876,470 Shares of Common Stock Pre-Funded Warrants to Purchase up to 300,000 Shares of Common Stock Warrants to Purchase up to 2,352,940 Shares of Common Stock We are offering 876,470 shares of common stock and accompanying warrants to purchase up to 1,752,940 shares of our common stock at a combined public offeri |
|
| May 23, 2023 |
As filed with the Securities and Exchange Commission on May 23, 2023 S-1/A Table of Contents As filed with the Securities and Exchange Commission on May 23, 2023 Registration No. |
|
| May 23, 2023 |
Form of Underwriting Agreement. EX-1.1 Exhibit 1.1 [•] Shares of Common Stock (or Pre-Funded Warrants to Purchase [•] Shares of Common Stock in Lieu Thereof) Warrants to Purchase [•] Shares of Common Stock BIOCEPT, INC. UNDERWRITING AGREEMENT May [•], 2023 EF Hutton, division of Benchmark Investments, LLC as Representative of the several Underwriters named on Schedule I hereto 590 Madison Avenue, 39th Floor New York, NY 10022 La |
|
| May 23, 2023 |
Calculation of Filing Fee Table. EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Biocept, Inc. |
|
| May 23, 2023 |
CORRESP May 23, 2023 VIA EDGAR Securities and Exchange Commission 100 F Street, N. |
|
| May 23, 2023 |
Biocept, Inc. 5810 Nancy Ridge Drive San Diego, CA 92121 CORRESP Biocept, Inc. 5810 Nancy Ridge Drive San Diego, CA 92121 May 23, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jessica Ansart Re: Biocept, Inc. Registration Statement on Form S-1, as amended (File No. 333-271355) Request for Acceleration of Effective Date Ladies and Gentlemen: Biocept, Inc. (the “Compa |
|
| May 19, 2023 |
Biocept, Inc. 5810 Nancy Ridge Drive San Diego, CA 92121 CORRESP Biocept, Inc. 5810 Nancy Ridge Drive San Diego, CA 92121 May 19, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jessica Ansart Re: Biocept, Inc. Registration Statement on Form S-1, as amended (File No. 333-271355) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 unde |
|
| May 19, 2023 |
As filed with the Securities and Exchange Commission on May 19, 2023 S-1/A Table of Contents As filed with the Securities and Exchange Commission on May 19, 2023 Registration No. |
|
| May 19, 2023 |
Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Biocept, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Fees to Be |
|
| May 19, 2023 |
CORRESP May 19, 2023 VIA EDGAR Securities and Exchange Commission 100 F Street, N. |
|
| May 19, 2023 |
EX-4.13 Exhibit 4.13 BIOCEPT, INC. WARRANT TO PURCHASE COMMON STOCK Warrant No.: [ ] Number of Shares of Common Stock: [ ] Date of Issuance: [ ], 2023 (“Issuance Date”) Biocept, Inc., a company organized under the laws of Delaware (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ], the registered holder her |
|
| May 18, 2023 |
Biocept, Inc. 5810 Nancy Ridge Drive San Diego, CA 92121 CORRESP Biocept, Inc. 5810 Nancy Ridge Drive San Diego, CA 92121 May 18, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jessica Ansart Re: Biocept, Inc. Registration Statement on Form S-1, as amended (File No. 333-271355) Ladies and Gentlemen: Biocept, Inc. (the “Company”) hereby withdraws its request, dated Ma |
|
| May 18, 2023 |
CORRESP May 18, 2023 VIA EDGAR Securities and Exchange Commission 100 F Street, N. |
|
| May 16, 2023 |
As filed with the Securities and Exchange Commission on May 16, 2023 S-1/A Table of Contents As filed with the Securities and Exchange Commission on May 16, 2023 Registration No. |
|
| May 16, 2023 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF BIOCEPT, INC. Biocept, Inc. (the “Company”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: FIRST: The name of this corporation is Biocept, Inc. and the date on which the Certificate of Incorporation of this corpora |
|
| May 16, 2023 |
Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Biocept, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Fees to Be |
|
| May 16, 2023 |
Biocept, Inc. 5810 Nancy Ridge Drive San Diego, CA 92121 CORRESP Biocept, Inc. 5810 Nancy Ridge Drive San Diego, CA 92121 May 16, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jessica Ansart Re: Biocept, Inc. Registration Statement on Form S-1, as amended (File No. 333-271355) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 unde |
|
| May 16, 2023 |
Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 16, 2023 |
Exhibit 4.13 BIOCEPT, INC. WARRANT TO PURCHASE COMMON STOCK Warrant No.: [ ] Number of Shares of Common Stock: [ ] Date of Issuance: [ ], 2023 (“Issuance Date”) Biocept, Inc., a company organized under the laws of Delaware (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ], the registered holder hereof or i |
|
| May 16, 2023 |
CORRESP May 16, 2023 VIA EDGAR Securities and Exchange Commission 100 F Street, N. |
|
| May 15, 2023 |
Biocept Reports First Quarter 2023 Financial Results EX-99.1 Exhibit 99.1 Biocept Reports First Quarter 2023 Financial Results SAN DIEGO (May 10, 2023) – Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2023 and provides a business update. “I’m exceptionally pleased with the progress being made with our FORESEE clinical trial, which |
|
| May 15, 2023 |
EX-4.13 Exhibit 4.13 BIOCEPT, INC. WARRANT TO PURCHASE COMMON STOCK Warrant No.: [ ] Number of Shares of Common Stock: [ ] Date of Issuance: [ ], 2023 (“Issuance Date”) Biocept, Inc., a company organized under the laws of Delaware (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ], the registered holder her |
|
| May 15, 2023 |
EX-4.14 Exhibit 4.14 BIOCEPT, INC. PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No.: [ ] Number of Shares of Common Stock: [ ] Date of Issuance: [ ], 2023 (“Issuance Date”) Biocept, Inc., a company organized under the laws of Delaware (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ], the registered |
|
| May 15, 2023 |
Form of Underwriting Agreement. EX-1.1 Exhibit 1.1 [•] Shares of Common Stock (or Pre-Funded Warrants to Purchase [•] Shares of Common Stock in Lieu Thereof) Warrants to Purchase [•] Shares of Common Stock BIOCEPT, INC. UNDERWRITING AGREEMENT May [•], 2023 EF Hutton, division of Benchmark Investments, LLC as Representative of the several Underwriters named on Schedule I hereto 590 Madison Avenue, 39th Floor New York, NY 10022 La |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 15, 2023 |
As filed with the Securities and Exchange Commission on May 15, 2023 S-1/A Table of Contents As filed with the Securities and Exchange Commission on May 15, 2023 Registration No. |
|
| May 15, 2023 |
Calculation of Filing Fee Table. EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Biocept, Inc. |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36284 Biocept, Inc. (Exact nam |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 20, 2023 |
S-1 Table of Contents As filed with the Securities and Exchange Commission on April 20, 2023 Registration No. |
|
| April 20, 2023 |
Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Biocept, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Fees to Be |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2023 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 17, 2023 |
Non-Employee Director Compensation Policy Exhibit 10.16 Exhibit 10.16 BIOCEPT, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) of Biocept, Inc. (the “Company”) who is a non-employee director of the Company (each such member, a “Non-Employee Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (the “Director Compensation Policy”). A Non-Emplo |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-36284 Biocept, Inc. |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36284 |
|
| April 17, 2023 |
Biocept Reports 2022 Financial Results EX-99.1 Exhibit 99.1 Biocept Reports 2022 Financial Results SAN DIEGO (April 17, 2023) – Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the 12 months ended December 31, 2022 and provides a business update. “I could not be prouder of my Biocept colleagues as together we have worked tirelessly to streamline operat |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 17, 2023 |
Exhibit 10.11 BIOCEPT, INC. Darrell Taylor, Esq. 1345 Belleview Avenue Cardiff, CA 92007 Re: Offer of Employment Dear Darrell: Biocept, Inc. (the “Company”) is pleased to offer you at-will employment in the position of Chief Legal and Compliance Officer (“CLO”) on the terms and conditions set forth in this letter agreement (the “Agreement”). 1. Employment by the Company. Your employment with the C |
|
| April 10, 2023 |
PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2023 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 10, 2023 |
EX-3.1 Exhibit 3.1 BIOCEPT, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Biocept, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by the board of directors of the Corp |
|
| April 10, 2023 |
EX-10.1 Exhibit 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (this “Agreement”) is made as of April 10, 2023, by and between the purchaser listed on Exhibit A attached hereto (the “Purchaser”) and Biocept, Inc., a Delaware corporation (the “Company”). RECITALS C. The Company desires to sell to the Purchaser, and the Purchaser desires to purchase from the Company, one share of Series B Preferred |
|
| April 3, 2023 |
NT 10-K SEC FILE NUMBER 001-36284 CUSIP NUMBER 09072V501 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| January 6, 2023 |
Biocept to Explore Strategic Alternatives and Implement Restructuring Plan Exhibit 99.1 Biocept to Explore Strategic Alternatives and Implement Restructuring Plan SAN DIEGO (January 6, 2023) ? Biocept, Inc. (NasdaqCM: BIOC) today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Biocept has engaged EF Hutton, division of Benchmark Investments, Inc., as its financial advisor to assist in this process. Po |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2023 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 21, 2022 |
Biocept Reports Third Quarter 2022 Financial Results EX-99.1 Exhibit 99.1 Biocept Reports Third Quarter 2022 Financial Results • CNSide™ study data featured in three poster presentations at leading neuro-oncology annual meeting • Participates in UCSF investigator-initiated study to better understand the development and progression of metastatic breast cancer to the central nervous system • CNSide orders increased 8% over 2Q 2022 and 176% versus 3Q 2 |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36284 Biocept, Inc. (Exact |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2022 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2022 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 14, 2022 |
NT 10-Q 1 d401145dnt10q.htm NT 10-Q SEC FILE NUMBER 001-36284 CUSIP NUMBER 09072V501 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ |
|
| November 14, 2022 |
Biocept Reports Second Quarter 2022 Financial Results Exhibit 99.1 Biocept Reports Second Quarter 2022 Financial Results ? Included first revenue from biopharma collaborator using CNSide? in their therapeutics clinical trial ? First site opened for patient enrollment in the FORESEE trial to generate evidence of CNSide?s clinical utility ? Expanded the commercial availability of CNSide to metastatic melanoma ? CNSide? orders increased 14% over 1Q 2022 |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36284 Biocept, Inc. (Exact name |
|
| November 10, 2022 |
EXHIBIT 10.1 SECOND AMENDMENT TO ASSIGNMENT AND EXCLUSIVE CROSS-LICENSE AGREEMENT THIS SECOND AMENDMENT TO ASSIGNMENTAND EXCLUSTVE CROSS-LICENSE AGREEMENT (the "Second Amendment") is entered into effective as of May 24, 2022 (the "Effective Date") by and between AEGEA BIOTECHNOLOGIES, a California corporation ("Aegea"), and BIOCEPT, INC., a Delaware corporation ("Biocept"). RECITALS WHEREAS, Aegea |
|
| October 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2022 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 22, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2022 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 16, 2022 |
NT 10-Q 1 d366135dnt10q.htm NT 10-Q SEC FILE NUMBER 001-36284 CUSIP NUMBER 09072V501 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Tran |
|
| July 14, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2022 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Number |
|
| July 14, 2022 |
Exhibit 99.1 TM Corporate Overview July 2022 Nasdaq: BIOC www.biocept.com 1 | ? 2022 Biocept, Inc. TM Forward-Looking Statements This presentation contains, and any accompanying oral presentation would no doubt contain, forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, regarding Biocept, Inc. and our business. Forward-looking statements include |
|
| July 13, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2022 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| June 27, 2022 |
Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2022 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2022 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 13, 2022 |
DEFA14A 1 d309090ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| May 24, 2022 |
Biocept Reports First Quarter 2022 Financial Results Exhibit 99.1 Biocept Reports First Quarter 2022 Financial Results ? Net revenues of $19.9 million up 12% over Q1 2021 ? CNSide? assay volume up 219% over Q1 2021 and up 70% over Q4 2021 ? Expanded CNSide customer base with additional oncologists from six leading cancer centers ? Previews re-focused and rationalized strategy following comprehensive business review Business update conference call to |
|
| May 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2022 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36284 Biocept, Inc. (Exact nam |
|
| May 23, 2022 |
Exhibit 10.1 BIOCEPT, INC. AMENDED AND RESTATED 2013 EQUITY INCENTIVE PLAN Adopted by the Board of Directors: July 31, 2013 Approved by the Stockholders: August 6, 2013 Amended and Restated by the Board of Directors: April 28, 2015 Approved by the Stockholders: June 16, 2015 Amended by the Board: July 25, 2016 Amended by the Board: March 27, 2017 Approved by the Stockholders: May 2, 2017 Amended b |
|
| May 16, 2022 |
NT 10-Q 1 d278697dnt10q.htm NT 10-Q SEC FILE NUMBER 001-36284 CUSIP NUMBER 09072V501 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Tra |
|
| May 2, 2022 |
DEF 14A 1 d231051ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com |
|
| April 12, 2022 |
Exhibit 16.1 April 11, 2022 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Commissioners: We have read Item 4.01 of Biocept, Inc.?s Form 8-K dated April 11, 2022, and we agree with the statements set forth in Item 4.01, insofar as they relate to our firm. We have no basis to agree or disagree with other statements made by the registrant contained in Item 4.01. Very tru |
|
| April 12, 2022 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2022 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 8, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Biocept, Inc. (Exact name of Registrant as Specified in its Charter) Table 1 ? Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Amended and Resta |
|
| April 8, 2022 |
As filed with the Securities and Exchange Commission on April 8, 2022 As filed with the Securities and Exchange Commission on April 8, 2022 Registration No. |
|
| April 8, 2022 |
Up to $10,219,945 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-237837 AMENDMENT NO. 1 DATED APRIL 8, 2022 To Prospectus Supplement dated May 12, 2021 (To Prospectus dated May 8, 2020) Up to $10,219,945 Common Stock We previously entered into a Controlled Equity OfferingSM Sales Agreement, or Sales Agreement, with Cantor Fitzgerald & Co., or Cantor, relating to shares of our common stock, $0.0001 par value |
|
| April 7, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2022 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 7, 2022 |
Biocept Reports 2021 Fourth Quarter and Full Year Financial Results Exhibit 99.1 Biocept Reports 2021 Fourth Quarter and Full Year Financial Results ? Fourth quarter net revenues of $14.0 million driven by RT-PCR COVID-19 testing volume ? Full year net revenues of $61.2 million increased 123% over the prior year ? Positive operating cash flow for 2021 of $3.7 million ? Cash and cash equivalents at 2021 year-end of $28.9 million ? CNSide? sequential-quarter volume |
|
| April 5, 2022 |
Exhibit 10.19 BIOCEPT, INC. February 15, 2022 Michael W. Nall [email protected] Dear Michael: This letter sets forth the substance of the separation agreement (the ?Agreement?) that Biocept, Inc. (the ?Company?) is offering to you to aid in your employment transition. 1.SEPARATION. Your last day of work with the Company and your employment termination date will be February 15, 2022 (the ?S |
|
| April 5, 2022 |
FIRST AMENDMENT TO EMPLOYMENT AGREEMENT Exhibit 10.15 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment to that certain Employment Agreement (this ?Amendment?) is entered into effective as of February 18, 2022, by and between Biocept, Inc., a Delaware corporation (?Company?), and Darrell Taylor (?Employee?). RECITALS Whereas, Company and Employee are parties to that certain Employment Agreement, made and effective as of Decem |
|
| April 5, 2022 |
Exhibit 10.20 BIOCEPT, INC. February 15, 2022 Timothy Kennedy [email protected] Dear Timothy: This letter sets forth the substance of the separation agreement (the ?Agreement?) that Biocept, Inc. (the ?Company?) is offering to you to aid in your employment transition. 1.SEPARATION. Your last day of work with the Company and your employment termination date will be February 15, 2022 (the ?Separa |
|
| April 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-36284 Biocept, Inc. |
|
| April 5, 2022 |
Exhibit 4.3 DESCRIPTION OF COMMON STOCK General The following description summarizes the material terms of our common stock. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description of the matters set forth in this ?Description of Common Stock,? you should refer to our amended and restated certificate of incorporation, as amende |
|
| April 5, 2022 |
Exhibit 10.16 BIOCEPT, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the ?Board?) of Biocept, Inc. (the ?Company?) who is a non-employee director of the Company (each such member, a ?Non-Employee Director?) will receive the compensation described in this Non-Employee Director Compensation Policy (the ?Director Compensation Policy?). A Non-Employee Director m |
|
| April 5, 2022 |
Exhibit 10.8 BIOCEPT, INC. AMENDED AND RESTATED 2013 EQUITY INCENTIVE PLAN Adopted by the Board of Directors: July 31, 2013 Approved by the Stockholders: August 6, 2013 Amended and Restated by the Board of Directors: April 28, 2015 Approved by the Stockholders: June 16, 2015 Amended by the Board: July 25, 2016 Amended by the Board: March 27, 2017 Approved by the Stockholders: May 2, 2017 Amended b |
|
| April 1, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 1, 2022 |
NT 10-K 1 d292275dnt10k.htm NT 10-K SEC FILE NUMBER 001-36284 CUSIP NUMBER 09072V501 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2021 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ |
|
| April 1, 2022 |
Biocept Reports Unaudited 2021 Revenue and Year-End Cash Balance Exhibit 99.1 Biocept Reports Unaudited 2021 Revenue and Year-End Cash Balance SAN DIEGO (March 31, 2022) ? Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports unaudited net revenue for 2021 of $61.2 million and cash and cash equivalents as of December 31, 2021 of approximately $28 million. ?Revenue reached a record high in 2021, up 123% o |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2022 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 24, 2022 |
Exhibit 3.1 SECOND AMENDMENT TO AMENDED AND RESTATED BYLAWS OF BIOCEPT, INC. The Amended and Restated Bylaws, as amended (the ?Bylaws?), of Biocept, Inc., a Delaware corporation (the ?Company?), are hereby amended as follows, effective as of March 22, 2022. 1. Section 5 of Article II of the Bylaws is hereby amended and restated in its entirety to read as follows: ?Section 5. Quorum; Adjournment. E |
|
| March 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2022 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 8, 2022 |
Exhibit 10.1 BIOCEPT, INC. March 4, 2022 Philippe Marchand, Ph.D. Re: Offer of Employment Dear Philippe: Biocept, Inc. (the ?Company?) is pleased to offer you at-will employment in the position of Chief Operations Officer (?COO?) on the terms and conditions set forth in this letter agreement (the ?Agreement?). 1. Employment by the Company. Your employment with the Company shall begin on March 7, 2 |
|
| February 16, 2022 |
Exhibit 10.2 BIOCEPT, INC. February 15, 2022 Re: Offer of Employment Dear Antonino: Biocept, Inc. (the ?Company?) is pleased to offer you at-will employment in the position of Interim Chief Financial Officer (?Interim CFO?) on the terms and conditions set forth in this letter agreement (the ?Agreement?). 1. Employment by the Company. Your employment with the Company shall begin on February 15, 202 |
|
| February 16, 2022 |
Exhibit 10.1 BIOCEPT, INC. February 15, 2022 Re: Offer of Employment Dear Samuel: Biocept, Inc. (the ?Company?) is pleased to offer you at-will employment in the position of Interim Chief Executive Officer (?Interim CEO?) on the terms and conditions set forth in this letter agreement (the ?Agreement?). 1. Employment by the Company. Your employment with the Company shall begin on February 15, 2022 |
|
| February 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2022 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36284 |
|
| January 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2022 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2021 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 16, 2021 |
November 16, 2021 (333-261093) As filed with the Securities and Exchange Commission on November 15, 2021 Registration No. |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36284 Biocept, Inc. (Exact |
|
| November 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 15, 2021 |
Biocept Reports Third Quarter 2021 Financial Results EX-99.1 2 bioc-ex9916.htm EX-99.1 EXHIBIT 99.1 Biocept Reports Third Quarter 2021 Financial Results • Revenues for the third quarter of $17.5 million, up 165% over prior-year quarter, driven by increased RT-PCR COVID-19 testing, resulting in profitability; cash balance of $27.7 million at quarter-end • Robust CNSide™ sequential-quarter volume growth; continued customer base expansion • Data genera |
|
| August 16, 2021 |
EXHIBIT 10.2 BIOCEPT, INC. AMENDED AND RESTATED 2013 EQUITY INCENTIVE PLAN Adopted by the Board of Directors: July 31, 2013 Approved by the Stockholders: August 6, 2013 Amended and Restated by the Board of Directors: April 28, 2015 Approved by the Stockholders: June 16, 2015 Amended by the Board: July 25, 2016 Amended by the Board: March 27, 2017 Approved by the Stockholders: May 2, 2017 Amended b |
|
| August 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2021 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36284 Biocept, Inc. (Exact name |
|
| August 16, 2021 |
Biocept Reports Second Quarter 2021 Financial Results EX-99.1 2 bioc-ex9916.htm EX-99.1 EXHIBIT 99.1 Biocept Reports Second Quarter 2021 Financial Results • Second quarter revenues of $12.0 million driven by RT-PCR COVID-19 testing • Continued sequential-quarter CNSide™ volume growth with customer base expanding to more than 30 leading U.S. academic institutions, including multiple repeat users • Issued coverage with high-value payment by Medicare fo |
|
| July 21, 2021 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2021 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Number |
|
| July 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2021 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Number |
|
| July 12, 2021 |
8-K/A 1 bioc-8ka20210611.htm 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2021 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other |
|
| June 15, 2021 |
8-K 1 bioc-8k20210611.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2021 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorpor |
|
| May 13, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 bioc-8k20210512.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorpora |
|
| May 13, 2021 |
Up to $25,000,000 Common Stock 424B5 1 bioc-424b5.htm 424B5 Filed pursuant to Rule 424(b)(5) Registration No. 333-237837 PROSPECTUS SUPPLEMENT (To Prospectus dated May 8, 2020) Up to $25,000,000 Common Stock We have entered into a sales agreement with Cantor Fitzgerald & Co., or Cantor Fitzgerald, relating to shares of our common stock, $0.0001 par value per share, offered by this prospectus supplement and the accompanying pros |
|
| May 13, 2021 |
EXHIBIT 1.1 BIOCEPT, INC. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement May 12, 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Biocept, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cantor Fitzgerald & Co. (the ?Agent?), as follows: 1.Issuance and Sale of Shares |
|
| May 12, 2021 |
Biocept Reports First Quarter 2021 Financial Results EXHIBIT 99.1 Biocept Reports First Quarter 2021 Financial Results ? Revenues of $17.8 million were driven by RT-PCR COVID-19 testing ? Initiated full commercial launch of CNSide? cerebrospinal fluid assay for diagnosing and managing patients with metastatic cancer involving the central nervous system ? Received approximately 390,000 COVID-19 samples since June 2020 ? Hosted KOL webinar with leadin |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36284 Biocept, Inc. (Exact nam |
|
| May 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 bioc-8k20210512.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorpora |
|
| April 30, 2021 |
DEF 14A 1 bioc-def14a20210611.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 31, 2021 |
Thanks, M UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-36284 Bioc |
|
| March 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 bioc-8k20210329.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2021 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorpo |
|
| March 29, 2021 |
EXHIBIT 99.1 Biocept Reports 2020 Fourth Quarter and Full Year Financial Results Q4 features revenues of $18.5 million; 2020 revenues reach $27.5 million driven by COVID-19 testing Introduces strategy to establish proprietary CSF assay as the standard of care in detecting cancer that has metastasized to the brain or central nervous system Conference call begins at 4:30 p.m. Eastern time today SAN |
|
| December 23, 2020 |
December 23, 2020 (333-251676) As filed with the Securities and Exchange Commission on December 23, 2020 Registration No. |
|
| December 23, 2020 |
EXHIBIT 99.1 BIOCEPT, INC. AMENDED AND RESTATED 2013 EQUITY INCENTIVE PLAN Adopted by the Board of Directors: July 31, 2013 Approved by the Stockholders: August 6, 2013 Amended and Restated by the Board of Directors: April 28, 2015 Approved by the Stockholders: June 16, 2015 Amended by the Board: July 25, 2016 Amended by the Board: March 27, 2017 Approved by the Stockholders: May 2, 2017 Amended b |
|
| November 16, 2020 |
EXHIBIT 4.2 Exhibit 4.2 COMMON STOCK THIS CERTIFIES THAT is the owner of Fully paid and non-assessable common shares, $0.0001 par value, of Biocept, inc. transferable on the books of the Corporation by the holder hereof in person or by attorney upon surrender of this certificate properly endo. This certificate is not valid until counteraigned and registered by the transfer Agent and Registrar. in |
|
| November 16, 2020 |
EXHIBIT 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into by and between Biocept, Inc., a Delaware corporation (the “Company”), and Michael Dugan, M.D. (“Employee”), and shall be effective as of August 10, 2020 (the “Effective Date”). Whereas, the Company desires to employ Employee, and Employee desires to accept employment with the Company, on the terms and co |
|
| November 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36284 Biocept, Inc. (Exact |
|
| November 12, 2020 |
EXHIBIT 99.1 Biocept Reports Third Quarter 2020 Financial Results Revenues of $6.6 million – a result of decision to offer COVID-19 testing Conference call begins at 4:30 p.m. Eastern time today SAN DIEGO (November 12, 2020) – Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable i |
|
| November 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| October 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2020 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Num |
|
| September 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2020 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File N |
|
| September 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2020 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| September 4, 2020 |
EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF Biocept, INC. Biocept, Inc. (the “Company”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: First: The name of this corporation is Biocept, Inc. and the date on which the Certificate of Incorporation of this corporation wa |
|
| August 21, 2020 |
Submission of Matters to a Vote of Security Holders - 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 3) CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2020 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Com |
|
| August 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36284 Biocept, Inc. (Exact name |
|
| August 13, 2020 |
EX-10.6 4 bioc-ex106261.htm EX-10.6 EXHIBIT 10.6 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment to Employment Agreement (the “Amendment”) is entered by and between Biocept, Inc., a Delaware corporation (the “Company”), and Michael Terry (“Employee”) and shall be effective as of September 11, 2018 (the “Amendment Effective Date”). Whereas, the Company and Employee are parties to that |
|
| August 13, 2020 |
Page - 1 EXHIBIT 10.4 FIFTH AMENDMENT TO LEASE This Fifth Amendment (this “Fifth Amendment“) to Lease is made as of 6/5, 2020, by and between ARE-SD REGION NO. 18, LLC, a Delaware limited liability company (“Landlord”), and BIOCEPT, INC., a Delaware corporation (“Tenant”). RECITALS A.Landlord and Tenant have entered into that certain Lease Agreement dated as of March 31, 2004, as amended by that c |
|
| August 13, 2020 |
EX-10.7 5 bioc-ex107260.htm EX-10.7 EXHIBIT 10.7 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into by and between Biocept, Inc., a Delaware corporation (the “Company”), and Cory Dunn(“Employee”), and shall be effective as of February 1, 2020 (the “Effective Date”). Whereas, the Company desires to ensure Employee continues her employment by the Company, and Employee |
|
| August 13, 2020 |
EXHIBIT 10.3 SINGLE-TENANT LEASE (TRIPLE NET) LANDLORD: 9955 MESA RIM, A DE LLC, a Delaware limited liability company TENANT: BIOCEPT, INC., a Delaware corporation TABLE OF CONTENTS Page 1. Lease of Premises1 2. Term2 3. Rent3 4. Triple-Net Lease4 5. Security Deposit5 6. Use5 7. Payments and Notices7 8. Brokers8 9. Surrender8 10. Taxes9 11. Repairs9 12. Alterations10 13. Liens11 14. Assignment and |
|
| August 12, 2020 |
EXHIBIT 99.1 Biocept Reports Second Quarter 2020 Financial Results Conference call begins at 4:30 p.m. Eastern time today SAN DIEGO (August 12, 2020) – Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients, reports financial results for the three and six months ended June |
|
| August 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2020 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 4, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 2) CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2020 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Com |
|
| July 16, 2020 |
DEFA14A 1 bioc-defa14a20200716.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by R |
|
| July 13, 2020 |
DEFA14A 1 bioc-defa14a20200709.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by R |
|
| July 1, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2020 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Com |
|
| June 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2020 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 10, 2020 |
EX-99.1 2 bioc-ex99118.htm EX-99.1 EXHIBIT 99.1 BIOCEPT, INC. AMENDED AND RESTATED 2013 EQUITY INCENTIVE PLAN Adopted by the Board of Directors: July 31, 2013 Approved by the Stockholders: August 6, 2013 Amended and Restated by the Board of Directors: April 28, 2015 Approved by the Stockholders: June 16, 2015 Amended by the Board: July 25, 2016 Amended by the Board: March 27, 2017 Approved by the |
|
| June 10, 2020 |
DEFA14A 1 bioc-defa14a20200610.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by R |
|
| June 5, 2020 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2020 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐Definitive Proxy Statemen |
|
| May 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36284 Biocept, Inc. (Exact nam |
|
| May 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2020 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 13, 2020 |
EXHIBIT 99.1 MAY 13, 2020 Biocept Reports First Quarter 2020 Financial Results Revenues of $1.4 million increased 41%, revenue per accession increased 27% Conference call begins at 4:30 p.m. Eastern time today SAN DIEGO (May 13, 2020) – Biocept, Inc. (NASDAQ: BIOC), a leading provider of molecular technologies designed to provide physicians with clinically actionable information to improve the out |
|
| April 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒Definitive Proxy Statemen |
|
| April 24, 2020 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. EXHIBIT 4.27 BIOCEPT, INC. and , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF [], 20 BIOCEPT, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT Preferred Stock Warrant Agreement (this “Agreement”), dated as of between Biocept, Inc., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having |
|
| April 24, 2020 |
As filed with the Securities and Exchange Commission on April 24, 2020 Registration No. |
|
| April 24, 2020 |
Form of Common Stock Warrant Agreement and Warrant Certificate. EXHIBIT 4.26 BIOCEPT, INC. and , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF [], 20 BIOCEPT, INC. FORM OF COMMON STOCK WARRANT AGREEMENT Common Stock Warrant Agreement (this “Agreement”), dated as of between Biocept, Inc., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having a corpor |
|
| April 24, 2020 |
Form of Indenture, between the Registrant and one or more trustees to be named. EXHIBIT 4.23 BIOCEPT, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities Table Of Contents Page article 1 DEFINITIONS1 Section 1.01 Definitions of Terms1 article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES5 Section 2.01 Designation and Terms of Securities5 Section 2.02 Form of Securities and Trustee’s Certificate8 Section 2.03 Deno |
|
| April 24, 2020 |
Specimen Common Stock certificate of Biocept, Inc. EXHIBIT 4.2 Common stock BIOC 1350 Biocept incorporated under the laws of the state of delaware see reverse side for certain definitions CUSIP 09072V 40 2 This certifies that is the owner of Fully paid and non-assessable common shares, $0.0001 par value, of Biocept, Inc. transferable on the books of the corporation by the holder hereof in person or by Attorney upon surrender of this certificate pr |
|
| April 24, 2020 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. EXHIBIT 4.28 BIOCEPT, INC. and , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF [], 20 BIOCEPT, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT Debt Securities Warrant Agreement (this “Agreement”), dated as of between Biocept, Inc., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having |
|
| April 20, 2020 |
BIOC / Biocept, Inc. PRE 14A - - PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐Definitive Proxy Statemen |
|
| April 15, 2020 |
Biocept, Inc. 22,300,000 Shares of Common Stock 424B5 1 bioc-424b5.htm 424B5 Filed pursuant to Rule 424(b)(5) Registration No. 333-224946 PROSPECTUS SUPPLEMENT (To Prospectus dated May 24, 2018) Biocept, Inc. 22,300,000 Shares of Common Stock We are offering 22,300,000 shares of our Common Stock, par value $0.0001 per share (the “Common Stock”), directly to certain institutional accredited investors pursuant to this prospectus supplement and th |
|
| April 15, 2020 |
[The remainder of this page has been intentionally left blank.] EXHIBIT 99.2 April 14, 2020 Mr. Michael W. Nall Chief Executive Officer and President Biocept, Inc. 5810 Nancy Ridge Drive San Diego, CA 92121 Dear Mr. Nall: This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and Biocept, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), pursuant to which the Placem |
|
| April 15, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2020 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 15, 2020 |
EXHIBIT 99.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 14, 2020, between Biocept, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth |
|
| April 15, 2020 |
Biocept Announces Pricing of $10.3 Million Registered Direct Offering Priced At-The-Market EXHIBIT 99.3 Biocept Announces Pricing of $10.3 Million Registered Direct Offering Priced At-The-Market SAN DIEGO (April 14, 2020) - Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today announced that on Ap |
|
| April 13, 2020 |
Financial Statements and Exhibits 8-K 1 bioc-8k20200409.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2020 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorpor |
|
| April 13, 2020 |
EXHIBIT 99.1 Biocept to Begin COVID-19 Testing Company to provide FDA-approved for EUA testing in its San Diego lab to assist physician clients in the fight against the coronavirus pandemic SAN DIEGO (April 9, 2020) – Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of pa |
|
| March 27, 2020 |
Exhibit 4.3 DESCRIPTION OF COMMON STOCK General The following description summarizes the material terms of our common stock. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description of the matters set forth in this “Description of Common Stock,” you should refer to our amended and restated certificate of incorporation, as amende |
|
| March 27, 2020 |
10-K 1 bioc-10k20191231.htm 10-K Thanks, M UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commi |
|
| March 25, 2020 |
Biocept Reports 2019 Fourth Quarter and Full Year Financial Results EXHIBIT 99.1 Biocept Reports 2019 Fourth Quarter and Full Year Financial Results • Fourth quarter revenues reached a record $1.8 million, up 108% over the fourth quarter of 2018 and up 17% over the third quarter of 2019 • Fourth quarter commercial revenues increased 94% over the fourth quarter of 2018 and increased 11% over the third quarter of 2019 • Fourth quarter cost of revenues per accession |
|
| March 25, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 bioc-8k20200325.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2020 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorpo |
|
| March 13, 2020 |
BIOC / Biocept, Inc. / INTRACOASTAL CAPITAL, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Biocept, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 09072V402 (CUSIP Number) March 2, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| March 5, 2020 |
EXHIBIT 99.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 4, 2020, between Biocept, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth |
|
| March 5, 2020 |
Biocept, Inc. 16,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-224946 PROSPECTUS SUPPLEMENT (To Prospectus dated May 24, 2018) Biocept, Inc. 16,000,000 Shares of Common Stock We are offering 16,000,000 shares of our Common Stock, par value $0.0001 per share (the “Common Stock”), directly to certain institutional accredited investors pursuant to this prospectus supplement and the accompanying prospectus. Ou |
|
| March 5, 2020 |
[The remainder of this page has been intentionally left blank.] EXHIBIT 99.2 March 4, 2020 Mr. Michael W. Nall Chief Executive Officer and President Biocept, Inc. 5810 Nancy Ridge Drive San Diego, CA 92121 Dear Mr. Nall: This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and Biocept, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), pursuant to which the Placeme |
|
| March 5, 2020 |
Biocept Announces Pricing of $6.6 Million Registered Direct Offering Priced At-The-Market EXHIBIT 99.3 Biocept Announces Pricing of $6.6 Million Registered Direct Offering Priced At-The-Market SAN DIEGO, March 5, 2020 - Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today announced that on March |
|
| March 5, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2020 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 3, 2020 |
Biocept Announces Pricing of $9.2 Million Registered Direct Offering Priced At-The-Market EXHIBIT 99.3 Biocept Announces Pricing of $9.2 Million Registered Direct Offering Priced At-The-Market SAN DIEGO, March 2, 2020 - Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today announced that it has e |
|
| March 3, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2020 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 3, 2020 |
EXHIBIT 99.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 2, 2020, between Biocept, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth |
|
| March 3, 2020 |
[The remainder of this page has been intentionally left blank.] EXHIBIT 99.2 March 2, 2020 Mr. Michael W. Nall Chief Executive Officer and President Biocept, Inc. 5810 Nancy Ridge Drive San Diego, CA 92121 Dear Mr. Nall: This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and Biocept, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), pursuant to which the Placeme |
|
| March 2, 2020 |
Biocept, Inc. 23,000,000 Shares of Common Stock 424B5 1 bioc-424b5.htm 424B5 Filed pursuant to Rule 424(b)(5) Registration No. 333-224946 PROSPECTUS SUPPLEMENT (To Prospectus dated May 24, 2018) Biocept, Inc. 23,000,000 Shares of Common Stock We are offering 23,000,000 shares of our Common Stock, par value $0.0001 per share (the “Common Stock”), directly to certain institutional accredited investors pursuant to this prospectus supplement and th |
|
| February 14, 2020 |
BIOC / Biocept, Inc. / Frigate Ventures LP - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A (Rule 13d-102) (Amendment No. |
|
| February 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Biocept, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 09072V402 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| January 15, 2020 |
BIOC / Biocept, Inc. / Empery Asset Management, LP - BIOCEPT, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Biocept, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 09072V402 (CUSIP Number) December 31, 2019 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| January 9, 2020 |
424B3 1 bioc-424b3.htm 424B3 Prospectus Supplement Filed Pursuant to Rule 424(b)(3) Registration File No. 333-228566 Warrants to Purchase 2,167,258 Shares of Common Stock (and up to 2,167,258 Shares of Common Stock Issuable Upon Exercise of Such Warrants) PROSPECTUS SUPPLEMENT NO. 1 DATED JANUARY 9, 2020 (To Prospectus Dated February 8, 2019) This Prospectus Supplement No. 1, dated January 9, 2020 |
|
| January 9, 2020 |
EXHIBIT 4.1 Amendment to Common Stock Purchase WarrantS This Amendment to Common Stock Purchase Warrants (this “Amendment”), dated as of January 9, 2020, is by and between Biocept, Inc., a Delaware corporation (the “Company”), and the undersigned holder (the “Holder”) of warrants to purchase shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”). Capitalized terms used |
|
| January 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2020 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 9, 2020 |
EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 11, 2019 |
EXHIBIT 99.1 Biocept Announces Pricing of $10.0 Million Underwritten Public Offering SAN DIEGO (December 9, 2019) – Biocept, Inc. (NASDAQ: BIOC) (“Biocept” or the “Company”), a leading commercial provider of liquid biopsy solutions, today announced the pricing of an underwritten public offering of 24,600,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereo |
|
| December 11, 2019 |
Financial Statements and Exhibits 8-K 1 bioc-8k20191209.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2019 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incor |
|
| December 11, 2019 |
EX-4.1 2 bioc-ex418.htm EX-4.1 EXHIBIT 4.1 COMMON STOCK PURCHASE WARRANT BIOCEPT, INC. Warrant Shares: [Initial Exercise Date: [, 2019 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date he |
|
| December 11, 2019 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-234459 PROSPECTUS 19,200,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 5,400,000 Shares of Common Stock Warrants to Purchase up to 24,600,000 Shares of Common Stock We are offering 19,200,000 shares of common stock and warrants to purchase up to 24,600,000 shares of our common stock at a combined public offering price of $0.4 |
|
| December 6, 2019 |
BIOC / Biocept, Inc. S-1/A - - S-1/A S-1/A 1 bioc-s1a.htm S-1/A As filed with the Securities and Exchange Commission on December 5, 2019 Registration No. 333-234459 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 4 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biocept, Inc. (Exact name of registrant as specified in its charter) Delaware 8071 80-0943522 (State or other jurisd |
|
| December 6, 2019 |
EXHIBIT 4.19 COMMON STOCK PURCHASE WARRANT BIOCEPT, INC. Warrant Shares: [Initial Exercise Date: [, 2019 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Da |
|
| December 5, 2019 |
EXHIBIT 4.19 COMMON STOCK PURCHASE WARRANT BIOCEPT, INC. Warrant Shares: [Initial Exercise Date: [, 2019 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Da |
|
| December 5, 2019 |
BIOC / Biocept, Inc. S-1/A - - S-1/A As filed with the Securities and Exchange Commission on December 4, 2019 Registration No. |
|
| December 4, 2019 |
BIOC / Biocept, Inc. CORRESP - - December 5, 2019 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| December 4, 2019 |
BIOC / Biocept, Inc. CORRESP - - Biocept, Inc. 5810 Nancy Ridge Drive San Diego, CA 92121 (858) 320-8200 December 5, 2019 Via Edgar United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn:Chris Edwards Re:Biocept, Inc. Registration Statement on Form S-1 File No. 333-234459 Acceleration Request Requested Date:Friday, December 6, 2019 Requested Time:9:05 a.m. E |
|
| November 15, 2019 |
BIOC / Biocept, Inc. S-1/A - - S-1/A S-1/A 1 bioc-s1a.htm S-1/A As filed with the Securities and Exchange Commission on November 15, 2019 Registration No. 333-234459 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biocept, Inc. (Exact name of registrant as specified in its charter) Delaware 8071 80-0943522 (State or other juris |
|
| November 15, 2019 |
Form of Underwriting Agreement EXHIBIT 1.1 SHARES of Common Stock, PRE-FUNDED warrants (exercisable for Shares) and Warrants (exercisable for Shares) of BIOCEPT, INC. UNDERWRITING AGREEMENT November [], 2019 Maxim Group LLC As Representative of the Several underwriters, if any, named in Schedule I hereto Investment Banking 405 Lexington Avenue, 2nd Fl. New York, NY 10174 Ladies and Gentlemen: The undersigned, BIOCEPT, INC., a c |
|
| November 13, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36284 Biocept, Inc. (Exact |
|
| November 13, 2019 |
Biocept Reports Third Quarter 2019 Financial Results EXHIBIT 99.1 Biocept Reports Third Quarter 2019 Financial Results • Revenues reached a record $1.5 million, up 101% over the third quarter of 2018 and up 28% over the second quarter of 2019 • The number of commercial samples received increased 66% over the third quarter of 2018 and 12% over the second quarter of 2019 • Cost of revenue reduced 23% on a per accession basis versus the third quarter o |
|
| November 13, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 bioc-8k20190930.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2019 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of inco |
|
| November 8, 2019 |
EXHIBIT 4.19 COMMON STOCK PURCHASE WARRANT BIOCEPT, INC. Warrant Shares: [Initial Exercise Date: [, 2019 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Da |
|
| November 8, 2019 |
EXHIBIT 4.20 PRE-FUNDED COMMON STOCK PURCHASE WARRANT BIOCEPT, INC. Warrant Shares: [Initial Exercise Date: [, 2019 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (th |
|
| November 8, 2019 |
BIOC / Biocept, Inc. S-1/A - - S-1/A As filed with the Securities and Exchange Commission on November 8, 2019 Registration No. |
|
| November 1, 2019 |
BIOC / Biocept, Inc. S-1 - Registration Statement - S-1 As filed with the Securities and Exchange Commission on November 1, 2019 Registration No. |
|
| September 27, 2019 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2019 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 14, 2019 |
August 15, 2019 (No. 333-233285) S-8 1 bioc-s8.htm S-8 As filed with the Securities and Exchange Commission on August 14, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOCEPT, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 80-0943522 (State or Other Jurisdiction of Incorporation or Organizat |
|
| August 14, 2019 |
10-Q 1 bioc-10q20190630.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 00 |
|
| August 12, 2019 |
Biocept Reports Second Quarter 2019 Financial Results EXHIBIT 99.1 Biocept Reports Second Quarter 2019 Financial Results • Second quarter 2019 revenues increased 45% and commercial samples increased 26% over the second quarter of 2018 • Revenues for the first six-month of 2019 increased 36% and commercial samples increased 18% over the first six months of 2018 • Conference call begins at 4:30 p.m. Eastern time today SAN DIEGO (August 12, 2019) – Bioc |
|
| August 12, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2019 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 18, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2019 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Number |
|
| July 18, 2019 |
EXHIBIT 10.1 AMENDMENT TO WARRANT Exercise Agreement This Amendment to Warrant Exercise Agreement (this “Amendment”), dated July 15, 2019, is by and between Biocept, Inc., a Delaware Corporation (the “Company”) and the undersigned holder (the “Holder”) of warrants to purchase shares of the Company’s common stock, par value $0.0001 per share. The Company and the Holder hereby agree to amend that ce |
|
| June 19, 2019 |
EXHIBIT 99.1 BIOCEPT, INC. 2013 AMENDED AND RESTATED EQUITY INCENTIVE PLAN Adopted by the Board of Directors: July 31, 2013 Approved by the Stockholders: August 6, 2013 Amended and Restated by the Board of Directors: April 28, 2015 Approved by the Stockholders: June 16, 2015 Amended by the Board: July 25, 2016 Amended by the Board: March 27, 2017 Approved by the Stockholders: May 2, 2017 Amended b |
|
| June 19, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2019 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 29, 2019 |
EXHIBIT 10.1 WARRANT EXERCISE AGREEMENT This Warrant Exercise Agreement (this “Agreement”), dated as of May 28, 2019, is by and between Biocept, Inc., a Delaware corporation (the “Company”), and the undersigned holder (the “Holder”) of warrants to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). WHEREAS, the Holder beneficially owns in the aggregate |
|
| May 29, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2019 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 29, 2019 |
EX-4.1 2 bioc-ex417.htm EX-4.1 EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT P |
|
| May 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36284 Biocept, Inc. (Exact nam |
|
| May 8, 2019 |
Biocept Reports First Quarter 2019 Financial Results EXHIBIT 99.1 Biocept Reports First Quarter 2019 Financial Results • Revenues increased 27% compared to the first quarter of 2018 • Billable samples grew 7% year over year, and increased 23% vs. the fourth quarter of 2018 • Commercial gains driven primarily by broadened pathology partnership service • Conference call begins at 4:30 p.m. Eastern time today SAN DIEGO (May 8, 2019) – Biocept, Inc. (NA |
|
| May 8, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2019 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 30, 2019 |
DEF 14A 1 bioc-def14a20190617.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 22, 2019 |
5,950,000 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-230797 5,950,000 Shares of Common Stock This prospectus relates to the disposition from time to time of up to 5,950,000 shares of our common stock by the selling stockholders named in this prospectus. Throughout this prospectus, when we refer to the shares of our common stock being registered on behalf of the selling stockholders for offer and |
|
| April 18, 2019 |
BIOC / Biocept, Inc. CORRESP - - Biocept, Inc. 5810 Nancy Ridge Drive San Diego, CA 92121 (858) 320-8200 April 18, 2019 Via Edgar United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re:Biocept, Inc. Registration Statement on Form S-1 File No. 333-230797 Ladies and Gentlemen: Pursuant to Rules 460 and 461 under the Securities Act of 1933, as amended, Biocept, I |
|
| April 16, 2019 |
As filed with the Securities and Exchange Commission on April 16, 2019 Registration No. |
|
| April 10, 2019 |
As filed with the Securities and Exchange Commission on April 10, 2019 Registration No. |
|
| March 29, 2019 |
Thanks, M UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-36284 Bioc |
|
| March 28, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2019 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 28, 2019 |
EXHIBIT 99.1 Biocept Reports 2018 Fourth Quarter and Full Year Financial Results Progress made implementing the Company’s commercial strategy highlighted by 7% sequential quarterly growth in billable test volume in the fourth quarter of 2018 compared to the third quarter of 2018 Capitalized to deliver on key initiatives in 2019 including growth from pathology partnership and liquid biopsy kit stra |
|
| March 15, 2019 |
Form of Securities Purchase Agreement EX-10.1 4 bioc-ex1019.htm EX-10.1 EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 15, 2019, between Biocept, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to |
|
| March 15, 2019 |
EX-99.1 6 bioc-ex9916.htm EX-99.1 EXHIBIT 99.1 Biocept Announces Pricing of $8.2 Million Registered Direct Offering SAN DIEGO (March 15, 2019) – Biocept, Inc. (NASDAQ: BIOC) (“Biocept” or the “Company”), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced it has entere |
|
| March 15, 2019 |
8-K 1 bioc-8k20190315.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2019 BIOCEPT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36284 80-0943522 (State or other jurisdiction of incorpo |
|
| March 15, 2019 |
EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 15, 2019 |
EXHIBIT 10.2 March 15, 2019 Mr. Michael W. Nall Chief Executive Officer and President Biocept, Inc. 5810 Nancy Ridge Drive San Diego, CA 92121 Dear Mr. Nall: This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim”), Dawson James Securities, Inc. (“DJ” and together with Maxim, the “Placement Agents”) and Biocept, Inc., a company incorporated under the laws of the St |
|
| March 15, 2019 |
Biocept, Inc. 5,950,000 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-224946 PROSPECTUS SUPPLEMENT (To Prospectus dated May 24, 2018) Biocept, Inc. 5,950,000 Shares of Common Stock We are offering 5,950,000 shares of our Common Stock, par value $0.0001 per share, or Common Stock, pursuant to this prospectus supplement and accompanying prospectus. In a concurrent private placement, we are also selling to the purch |
|
| February 19, 2019 |
BIOC / Biocept, Inc. / INTRACOASTAL CAPITAL, LLC - SCHEDULE 13G Passive Investment SC 13G 1 sc13g0219intracoastalbioce.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Biocept, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 09072V402 (CUSIP Number) February 12, 2019 (Date of Event Which Requires Filing of this Statement) |
|
| February 19, 2019 |
EX-99.1 2 d696088dex991.htm EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, par value $0.0001 per share, of Biocept, Inc., a Delaware corpor |
|
| February 19, 2019 |
BIOC / Biocept, Inc. / Frigate Ventures LP - SC 13G Passive Investment SC 13G 1 d696088dsc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) Biocept, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 09072V402 (CUSIP Number) February 8, |
|
| February 13, 2019 |
BIOC / Biocept, Inc. / Tierney Daniel - SC 13G AMENDMENT NO. 1 Passive Investment SC 13G Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Biocept, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share ( |
|
| February 8, 2019 |
6,250,000 Shares of Common Stock Warrants to Purchase up to 6,250,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(4) Registration No. 333-228566 PROSPECTUS 6,250,000 Shares of Common Stock Warrants to Purchase up to 6,250,000 Shares of Common Stock Biocept, Inc. is offering 6,250,000 shares of common stock and warrants to purchase up to 6,250,000 shares of our common stock, at a combined offering price of $1.20 per share of common stock and accompanying warrant. Each share of our |
